The exposure of endothelial cells (EC) to fibrin has been shown to stimulate the rapid release of von Willebrand factor (vWf) from storage sites in Weibel-Palade bodies. We have now investigated the fibrin structural features required for stimulation of release. The role of fibrinopeptide cleavage was examined by preparing fibrin with thrombin to remove both fibrinopeptide A (FPA) and fibrinopeptide B (FPB) and with reptilase or Agkistrodon contortrix procoagulant to selectively remove FPA or FPB, respectively. vWf release was found to require FPB cleavage, whereas removal of FPA and Factor XIII, cross-linking of fibrin were without effect. The dependence of release on FPB cleavage suggested that a site involving the NH2 terminus of the ,8 chain could mediate vWf secretion. To test this hypothesis, B,B chain derivatives were prepared and examined for their capacity to induce release.
Introduction
Fibrin interacts with endothelial cells at sites of inflammation, vascular injury, and thrombosis, resulting in several effects on hemostasis and endothelial cell (EC)' function. Exposure of a confluent endothelial monolayer to fibrin causes cell retrac-tion, disruption of cellular organization, and separation of the monolayer into migratory cells (1) . Both fibrin and fibrin degradation products have been shown to stimulate EC migration (1) (2) (3) and disorganization during angiogenesis (4) (5) (6) . EC exposed to fibrin increase secretion ofboth prostacyclin, a potent vasodilator and inhibitor of platelet aggregation, and tissue plasminogen activator, an inducer of fibrinolytic activity (7) .
Fibrin may also affect hemostasis by causing release ofvWf from its storage sites in the Weibel-Palade bodies of EC (8) . vWf is a large adhesive glycoprotein synthesized by EC (9) and megakaryocytes (10, 1 1) that is required for adhesion of platelets to the subendothelium at sites of vascular injury (12, 13) and also supports the platelet interactions resulting in formation of platelet aggregates (14, 15) . The importance of vWf in hemostasis is reflected in the occurrence of the bleeding disorder, von Willebrand's disease, resulting from deficient or defective vWf (16) . vWf is structurally heterogeneous, consisting of disulfide-bound multimers varying in molecular weight from 500,000 to 20,000,000 as shown by SDS agarose gel electrophoresis (17, 18) , with the larger forms having greater biological activity than the smaller (19) . Because vWfstored in EC Weibel-Palade bodies consists of only the largest multimers (20, 21) , fibrin-induced secretion can provide highly functional vWf to facilitate local hemostasis.
Fibrinogen is a bivalent molecule composed ofsix polypeptide chains, two each ofthe Aa, B$, and y chains. These chains are disulfide bonded near their amino termini, to form a central domain with the carboxyl ends of the chains extending laterally, forming two lateral domains (22) . Thrombin cleaves fibrinogen near the amino ends of the Aa and B,B chains liberating fibrinopeptide A (FPA) and fibrinopeptide B (FPB) (23, 24) , and generating fibrin monomers that polymerize to form an insoluble gel. Fibrin may be further stabilized by the Factor XIII.-catalyzed formation of intermolecular e-(y-glutamyl) lysine isopeptide bonds between y chains ofadjacent monomers (25) and also among two or more a chains (26, 27) . Stabilized fibrin forms the supporting matrix of a hemostatic plug or thrombus and is proteolytically degraded by the fibrinolytic system.
Our previous studies (8) (29) . Procoagulant fractions having no fibrinolytic activity were identified as those that yielded a firm clot after a 3-h incubation at 37°C with fibrinogen (2.3 mg/ml) and that did not lyse with continued incubation for 18 h. These column fractions were pooled and stored at -20°C. The protein concentrations in pooled fractions were determined to be 90 ,g/ml using the Bradford method (30).
Preparation ofclots. Non-cross-linked fibrin was prepared from 3 mg/ml of Factor XIII-deficient fibrinogen in HBSS with 10 mM calcium chloride and 5 X Io-' U/ml thrombin, 1.1 batroboxin unit/ml of reptilase or 40 ,ug/ml of procoagulant column pool of the contortrix venom. 0.7-ml aliquots were clotted in a humidity chamber for 6-18 h. Cross-linked fibrin was prepared in the same way with the addition of 1 U/ml of preactivated Factor XIII before clotting. Factor XIII purified from human placenta (Behringwerke Hoechst-Roussel, Somerville, NJ) that contained only a chains were activated with 1 U/ml thrombin in 10 mM calcium chloride at 37°C for 30 min, after which the thrombin was inhibited by adding 10 U/ml hirudin (Sigma Chemical Co.). Because fibrinopeptide cleavage by the contortrix enzyme is temperature dependent (29, 31) , clots formed with this enzyme were prepared at 4°C, favoring cleavage of FPB, whereas thrombin and reptilase clots were formed at 25°C. All clots were rinsed three times with HBSS containing 1 U/ml hirudin at 25°C before incubation with cells. Supematants from contortrix clots were prepared by removing the fibrin and centrifuging at 12,000 g for 2 min. The supernatant from a single clot was added to 1 ml of media containing 10 A plasmin digest of fibrinogen was prepared using a modification of the methods of Kudryk and colleagues (37) . Fibrinogen was diluted to 4 mg/ml in 0.037 M Tris, 0.15 M sodium chloride, 0.1% sodium azide, 0.01 M calcium chloride, pH 7.3, and then incubated for 90 min at 37°C with 100 U/ml streptokinase (Kabi Vitrum, Stockholm). The digest was filtered through a l0,000-M, cutoff filter (Amicon Corp., Lexington, MA) and the filtrate was found to contain 30 yg/ml protein by Bradford analysis (30). A portion ofthe filtrate was incubated with 1 U/ml thrombin for 30 min and then treated with 10 U/ml hirudin to inhibit the thrombin activity.
B, 1 -42 was prepared from plasmic digests of human fibrinogen as described by Skogen et al. (38) . HPLC purification was conducted on a 250 X 10 mm Hi-Pore-318 C18 semipreparative reverse phase column (Bio-Rad Laboratories, Rockville Center, NY) with a biphasic linear 0-25% acetonitrile gradient (38) generated by an automated gradient controller and pump (Model 510; Waters Associates). Absorbance was detected at 214 nm on an absorbance detector (model 441; Waters Associates). Polypeptide-containing peaks were collected, lyophilized, and analyzed for amino acid composition as described above (34) . Material from selected peaks was redissolved in a minimum volume of 0.02 M Tris-maleate, 0.1 % sodium chloride, 0.01 M calcium chloride, pH 7.4, and treated with 10 U/ml thrombin to identify thrombin-sensitive peptides. After a 1-h incubation, the peptides were rechromatographed on the same column and the peaks produced by the thrombin cleavage, B,B1-14 (FPB), B,B2-14, and # 15-42, were collected, lyophilized, and analyzed for amino acid composition (34) .
(B1 5-42 was synthetically prepared by a modification of the solidphase peptide synthesis procedure (39, 40) using a peptide synthesizer (Model 430A; Applied Biosystems, Inc., Foster City, CA). The t-butoxy-carbonylamino acids were sequentially coupled as symmetric anhydrides onto a phenyl-acetamidomethyl (OCH2PAM) resin (Applied Biosystems, Inc.) with double coupling cycles used for all arginine residues. The remainder of the synthesis, purification, and characterization ofthe peptide were conducted as described (40) . Peptide /31 5-18 (GHRP) was purchased from Sigma Chemical Co.
Cell culture and immunofluorescence. Human umbilical vein EC were grown in culture as described elsewhere (41, 42) . Primary cultures plated on glass coverslips were grown in McCoy's 5A media (Flow Laboratories, Inc., McLean, VA) containing 20% fetal bovine serum (Hyclone Laboratories, Logan, UT). Fibrin stimulation of vWf release with preformed clots was carried out as described (8) except that all incubations were conducted at 25°C instead of 37°C because the contortrix-formed fibrin dissociated above 25°C (31 
Results
EC stimulation by fibrin. Cross-linked and non-cross-linked fibrin were prepared using thrombin, reptilase, or contortrix to remove fibrinopeptides selectively, and the polypeptide chain composition was characterized by SDS-PAGE (Fig. 1) . The y chains for all three types of non-cross-linked fibrin demonstrated the same mobility as did fibrinogen, consistent with absence of cleavage in this chain. Upon cross-linking (Fig. 1 FPA cleavage in the contortrix clot could not be readily demonstrated because this enzyme cleaved the proteolytically sensitive, carboxy-terminal end of the a chain, also resulting in increased mobility (29) . The extent of fibrinopeptide cleavage was determined by quantitative HPLC analysis (Table I) . Thrombin cleaved both FPA and FPB completely, whereas reptilase cleaved only FPA but not FPB. The contortrix enzyme preferentially cleaved FPB at 4°C producing fibrin, from which 90% of FPB but only 21% of FPA was removed.
The stimulatory abilities of the fibrins was assessed after immunofluorescent staining of EC for vWf after a 10-min incubation with fibrin (Table I, Fig. 2 ). Control cells demonstrated diffuse perinuclear staining of the vWf reflecting the presence of the protein in the endoplasmic reticulum and Golgi apparatus, and also showed staining of the rod-shaped cytoplasmic storage granules, the Weibel-Palade bodies (Fig. 2,  arrowheads) . Control cells in both the presence and absence of factor XIIIa demonstrated a basal level of vWf secretion (Table  I) . After stimulation with non-cross-linked or cross-linked reptilase-made clots the vWf distribution was unchanged from untreated controls (Table I, Fig. 2 ). In contrast, after stimulation with non-cross-linked or cross-linked thrombin-or contortrix-made fibrin, the staining pattern of the cells changed, and the Weibel-Palade bodies were replaced by bright patches of cell surface vWf staining (Fig. 2, arrows) with nearly complete release (Table I) . Neither contortrix venom alone nor the supernatant from the contortrix clots stimulated release above background. When clots were made using 5 X 103 U/ml thrombin at 4°C for 6 h, HPLC analysis revealed that 53% of FPA and only 10% of FPB was removed. These clots were unable to stimulate the EC, with 10 and 26% of the cells secreting after treatment with a non-cross-linked or cross-linked clot, respectively. These data demonstrate a correlation of FPB cleavage with fibrin stimulation ability, but no apparent effect of either FPA cleavage or fibrin cross-linking. (Table II) . However, the same preparation stimulated 73% release after incubation with thrombin, indicating that thrombin-cleaved plasmic peptides retained activity. B#31-42 was purified from the Mr < 10,000 fraction by HPLC, eluting as a single peak after rechromatography (Fig. 4 A), and its identity was confirmed by amino acid analysis (Table III) . After cleavage by thrombin (10 U/ml), two major peaks were produced (Fig. 4 B) and amino acid analysis of these peaks confirmed their identity as FPB and ,B 15-42 ( (Fig. 4 B) . Cells incubated with 0.1 mM concentrations of BPB1-42 did not stimulate release significantly above control (Table IV) , but release was stimulated at 3 h by either purified or synthetic peptide at concentrations of 0.1 and 1 mM (P < 0.005). No release was seen with FPB or with the peptide GHRP representing the four NH2-terminal amino acid residue of the (3 chain.
To confirm release with # chain and with (315-42, EC were metabolically labeled, and released vWf was immunopurified and characterized by SDS-PAGE (Fig. 5) . The vWfreleased by A23187, (3 nM for the B(3 chains before and after thrombin cleavage were both statistically significant (P < 0.05 and < 0.025, respectively). Bars represent the mean of three to five determinations±SE. pared with three enzymes differing in specificity for fibrinopeptide cleavage. Release of vWf was stimulated by fibrin prepared with either thrombin, which cleaves both FPA and FPB, or with the contortrix procoagulant, which cleaves primarily FPB (Table I) . Release did not occur with exposure of EC to fibrin prepared with reptilase, which removes only FPA (Table  I) , confirming our prior report (8) . The results further indicate that stimulation of release is independent of Factor XIIIa-mediated fibrin cross-linking, as both non-cross-linked and cross-linked fibrin were stimulatory after FPB cleavage (Table  I ). The stimulation of release by fibrin prepared with contortrix procoagulant confirms previous findings indicating that fibrin induced release was not caused by small amounts of fibrin-bound thrombin (8) . Figure 4 . HPLC elution patterns of peptides derived from plasma digestion of fibrinogen. Fibrinogen was digested for 30 min at 37°C with 0.02 U/ml plasmin, the large molecular weight proteins precipitated with 4 0.05% TCA and the supernatant fil- ¶ tered through a 10,000 M, cut-off membrane after centrifugation. The peptides were separated by HPLC on a RP-C18 318 semipreparative column (Bio-Rad Laboratories) as described by Skogen et al. (38) and peaks containing B(3142 were identified. The pool of Bl1-42 was rechromatographed (A) and was composed of a single peak. Treatment of this sample with 10 U/ml thrombin for 2 h at 25°C (B) produced two major peaks, found by amino acid analysis to be and FPB.
The results with purified Bj3 chain and B(3 chain peptides implicate a site near the NH2 terminus of the (3 chain in mediating vWf release. The B,B chain showed minimal activity at 200 nM, whereas significant release occurred at 20 nM after thrombin cleavage (Fig. 3) . The finding that a low relative molecular mass fraction of a plasmic digest of fibrinogen stimulated release after thrombin cleavage (Table II) , is also consistent with involvement ofa site at the , chain NH2 terminus, because B(3 1-42 is cleaved early during plasmic degradation of fibrinogen (38) and contains the argl4-glyl 5 bond that is sen- sitive to cleavage by thrombin. To confirm the involvement of a site at the 3 chain NH2 terminus, we purified B,B1 -42, ,315-42, and FPB (Fig. 4) and found that only j315-42 had stimulatory activity (Table IV) . Release was confirmed by immunopurification of released vWf after exposure of EC to ,B chain or #31 5-42 (Fig. 5) . The released vWf was composed of mature, highly processed subunits, and released in equal amount to the propolypeptide (Fig. 5) , indicating that it derived from Weibel-Palade bodies (20) . None ofthe soluble derivatives was as active in stimulating release as intact fibrin, as these preparations stimulated less at 3 h than intact fibrin stimulated at 10 min. One potential explanation for this finding is that the complete active site includes structures contained on the a or y chain present in intact fibrin but absent in the 13 chain peptides. A second explanation for the slower release with peptides is that the necessary conformation of the ,B chain for stimulation is stabilized in intact fibrin, and this is consistent with the greater activity of the whole 13 (46) . FPB and plasmic peptides of fibrinogen and fibrin have been shown to cause EC shape change and stimulation of migration in culture (47) . Additional effects on EC include the reported vasoconstrictor activity of FPB (46) and the vasodilation and increased vascular permeability stimulated by 1343-47 (46, 48) . FPB and B,B1-42 have effects on other cell types including the stimulation of migration ofneutrophils (49-51), monocytes (52) , and fibroblasts (49, 50). Plasmic peptides of fibrinogen, including ,B43-47 inhibit thymidine uptake in stimulated lymphocytes (53, 54) suggesting that they have immunosuppressive effects. The findings in this report demonstrate that removal ofFPB is necessary for expression of vWf releasing activity since neither intact fibrinogen nor B131-42 had activity. This indicates that EC specifically recognize the amino terminus of the 13 chain, possibly by a receptor-mediated mechanism. The recent findings by Chen et al. (55) that ,B15-42 inhibits platelet aggregation and binding to activated platelets is consistent with this hypothesis. Together, the evidence suggests an important role for sites near the NH2 terminus of the B,B or 13 chain in modulating the cellular changes accompanying hemostasis and inflammation at sites of fibrin deposition.
